Iqvia (NYSE:IQV) Stock Price Up 9.7%

Iqvia Holdings Inc (NYSE:IQV) shares rose 9.7% on Wednesday . The company traded as high as $97.09 and last traded at $106.30, approximately 82,838 shares traded hands during trading. A decline of 97% from the average daily volume of 2,821,958 shares. The stock had previously closed at $96.91.

Several equities analysts have commented on the stock. ValuEngine upgraded shares of Iqvia from a “sell” rating to a “hold” rating in a report on Saturday, February 15th. JPMorgan Chase & Co. upped their price objective on shares of Iqvia from $180.00 to $195.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Wells Fargo & Co assumed coverage on shares of Iqvia in a report on Tuesday, January 7th. They issued an “overweight” rating and a $180.00 price objective on the stock. Barclays decreased their price objective on shares of Iqvia from $192.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, Robert W. Baird upped their price objective on shares of Iqvia from $172.00 to $181.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Iqvia currently has a consensus rating of “Buy” and a consensus target price of $169.06.

The stock’s 50-day moving average price is $137.77 and its 200-day moving average price is $147.00. The company has a market cap of $18.64 billion, a P/E ratio of 113.97, a PEG ratio of 1.05 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.05 and a quick ratio of 1.05.

Iqvia (NYSE:IQV) last announced its earnings results on Wednesday, February 12th. The medical research company reported $1.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. The company had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.85 billion. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. Iqvia’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.50 earnings per share. As a group, analysts expect that Iqvia Holdings Inc will post 6.62 EPS for the current fiscal year.

In other news, CFO Michael R. Mcdonnell sold 12,000 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total value of $1,860,840.00. Following the completion of the sale, the chief financial officer now owns 14,366 shares of the company’s stock, valued at $2,227,735.62. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Michael J. Evanisko sold 6,250 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $160.76, for a total transaction of $1,004,750.00. The disclosure for this sale can be found here. In the last three months, insiders sold 740,828 shares of company stock valued at $121,469,155. 6.00% of the stock is currently owned by company insiders.

Several institutional investors have recently made changes to their positions in IQV. RMR Wealth Builders bought a new stake in Iqvia during the fourth quarter worth about $27,000. Penserra Capital Management LLC lifted its position in Iqvia by 57.5% during the fourth quarter. Penserra Capital Management LLC now owns 189 shares of the medical research company’s stock worth $29,000 after purchasing an additional 69 shares during the period. Orion Portfolio Solutions LLC bought a new stake in Iqvia during the fourth quarter worth about $32,000. Patriot Financial Group Insurance Agency LLC lifted its position in Iqvia by 379.5% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock worth $33,000 after purchasing an additional 167 shares during the period. Finally, Evolution Wealth Advisors LLC lifted its position in Iqvia by 303.6% during the fourth quarter. Evolution Wealth Advisors LLC now owns 222 shares of the medical research company’s stock worth $34,000 after purchasing an additional 167 shares during the period. 89.25% of the stock is owned by institutional investors.

Iqvia Company Profile (NYSE:IQV)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: Put Option

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.